Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
Location: Sweden, Scania, Lund
Employees: 11-50
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | Hadean Ven... | hadeanvent... |
Mentions in press and media 27
| Date | Title | Description | Source |
| 08.04.2024 | BioStock: Abliva’s mission to become mitochondrial medicine ... | BioStock: Abliva’s mission to become mitochondrial medicine powerhouse Mon, Apr 08, 2024 09:16 CET R... | news.cisio... |
| 13.10.2023 | Abliva Achieves Important Milestone in the Ongoing FALCON St... | Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of ra... | hadeanvent... |
| 05.09.2023 | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Desig... | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation Abliva AB (Nasdaq Stockholm: ABL... | hadeanvent... |
| 01.06.2022 | Abliva decides on a SEK 200 million financing to fund Phase ... | - | hadeanvent... |
| 14.01.2022 | Resolution at the Extraordinary General Meeting in Abliva AB... | Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary Gener... | marketscre... |
| 21.12.2021 | Notice of Extraordinary General Meeting of Abliva AB (publ) | The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to ... | marketscre... |
| 21.12.2021 | Abliva resolves on directed issue of convertibles amounting ... | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, ... | marketscre... |
| 25.10.2021 | Abliva : Notice AGM 2021 (pdf) | Press Release Abliva AB (publ), 556595-6538 19 April 2021 16:10:00 CEST - Lund, Sweden Notice of Ann... | marketscre... |
| 17.09.2021 | Abliva : to participate in World Mitochondrial Disease Week ... | Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines ... | marketscre... |
| 19.08.2021 | Abliva : Interim Report January – June 2021 | Second quarter summary Phase 1a/b study: positive placebo-controlled safety data for KL1333 and the ... | marketscre... |
Show more